650 related articles for article (PubMed ID: 28913575)
1. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2).
Zinman B; Marso SP; Poulter NR; Emerson SS; Pieber TR; Pratley RE; Lange M; Brown-Frandsen K; Moses A; Ocampo Francisco AM; Barner Lekdorf J; Kvist K; Buse JB;
Diabetologia; 2018 Jan; 61(1):48-57. PubMed ID: 28913575
[TBL] [Abstract][Full Text] [Related]
2. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality.
Pieber TR; Marso SP; McGuire DK; Zinman B; Poulter NR; Emerson SS; Pratley RE; Woo V; Heller S; Lange M; Brown-Frandsen K; Moses A; Barner Lekdorf J; Lehmann L; Kvist K; Buse JB;
Diabetologia; 2018 Jan; 61(1):58-65. PubMed ID: 28913543
[TBL] [Abstract][Full Text] [Related]
3. Devoting attention to glucose variability and hypoglycaemia in type 2 diabetes.
Rutter MK
Diabetologia; 2018 Jan; 61(1):43-47. PubMed ID: 28913602
[TBL] [Abstract][Full Text] [Related]
4. Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials.
DeVries JH; Bailey TS; Bhargava A; Gerety G; Gumprecht J; Heller S; Lane W; Wysham CH; Zinman B; Bak BA; Hachmann-Nielsen E; Philis-Tsimikas A
Diabetes Obes Metab; 2019 Mar; 21(3):622-630. PubMed ID: 30362250
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7).
Pratley RE; Emerson SS; Franek E; Gilbert MP; Marso SP; McGuire DK; Pieber TR; Zinman B; Hansen CT; Hansen MV; Mark T; Moses AC; Buse JB;
Diabetes Obes Metab; 2019 Jul; 21(7):1625-1633. PubMed ID: 30850995
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Outcomes Trials Update: Insights from the DEVOTE Trial.
Bilal A; Pratley RE
Curr Diab Rep; 2018 Sep; 18(11):102. PubMed ID: 30229352
[TBL] [Abstract][Full Text] [Related]
7. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14.
Pratley RE; Husain M; Lingvay I; Pieber TR; Mark T; Saevereid HA; Møller DV; Zinman B;
Cardiovasc Diabetol; 2019 Nov; 18(1):156. PubMed ID: 31729990
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Marso SP; McGuire DK; Zinman B; Poulter NR; Emerson SS; Pieber TR; Pratley RE; Haahr PM; Lange M; Brown-Frandsen K; Moses A; Skibsted S; Kvist K; Buse JB;
N Engl J Med; 2017 Aug; 377(8):723-732. PubMed ID: 28605603
[TBL] [Abstract][Full Text] [Related]
9. Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9).
Pollock RF; Heller S; Pieber TR; Woo V; Gundgaard J; Hallén N; Luckevich M; Tutkunkardas D; Zinman B;
Diabetes Obes Metab; 2019 Jul; 21(7):1706-1714. PubMed ID: 30924579
[TBL] [Abstract][Full Text] [Related]
10. Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTE.
Klein KR; Franek E; Marso S; Pieber TR; Pratley RE; Gowda A; Kvist K; Buse JB
BMJ Open Diabetes Res Care; 2021 Nov; 9(2):. PubMed ID: 34819298
[TBL] [Abstract][Full Text] [Related]
11. Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial.
Pieber TR; Arfelt KN; Cailleteau R; Hart M; Kar S; Mursic I; Svehlikova E; Urschitz M; Haahr H
Diabetologia; 2023 Aug; 66(8):1413-1430. PubMed ID: 37308751
[TBL] [Abstract][Full Text] [Related]
12. Risk of major cardiovascular events, severe hypoglycaemia, and all-cause mortality for users of insulin degludec versus insulin glargine U100-A Danish cohort study.
Jensen MH; Hejlesen O; Vestergaard P
Diabetes Metab Res Rev; 2020 Jan; 36(1):e3225. PubMed ID: 31647163
[TBL] [Abstract][Full Text] [Related]
13. Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE.
Heller S; Lingvay I; Marso SP; Philis-Tsimikas A; Pieber TR; Poulter NR; Pratley RE; Hachmann-Nielsen E; Kvist K; Lange M; Moses AC; Andresen MT; Buse JB;
Diabetes Obes Metab; 2020 Dec; 22(12):2241-2247. PubMed ID: 32250536
[TBL] [Abstract][Full Text] [Related]
14. Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2.
Heller SR; DeVries JH; Wysham C; Hansen CT; Hansen MV; Frier BM
Diabetes Obes Metab; 2019 Jul; 21(7):1634-1641. PubMed ID: 30891886
[TBL] [Abstract][Full Text] [Related]
15. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
Roussel R; Ritzel R; Boëlle-Le Corfec E; Balkau B; Rosenstock J
Diabetes Metab; 2018 Nov; 44(5):402-409. PubMed ID: 29548798
[TBL] [Abstract][Full Text] [Related]
16. Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus.
Philis-Tsimikas A; Astamirova K; Gupta Y; Haggag A; Roula D; Bak BA; Fita EG; Nielsen AM; Demir T
Diabetes Res Clin Pract; 2019 Jan; 147():157-165. PubMed ID: 30448451
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
[TBL] [Abstract][Full Text] [Related]
18. Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10).
Brown-Frandsen K; Emerson SS; McGuire DK; Pieber TR; Poulter NR; Pratley RE; Zinman B; Ranthe MF; Grøn R; Lange M; Moses AC; Örsy P; Buse JB;
Diabetes Obes Metab; 2019 Jun; 21(6):1437-1444. PubMed ID: 30793465
[TBL] [Abstract][Full Text] [Related]
19. A higher non-severe hypoglycaemia rate is associated with an increased risk of subsequent severe hypoglycaemia and major adverse cardiovascular events in individuals with type 2 diabetes in the LEADER study.
Heller SR; Geybels MS; Iqbal A; Liu L; Wagner L; Chow E
Diabetologia; 2022 Jan; 65(1):55-64. PubMed ID: 34704120
[TBL] [Abstract][Full Text] [Related]
20. The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design.
Agesen RM; Alibegovic AC; Andersen HU; Beck-Nielsen H; Gustenhoff P; Hansen TK; Hedetoft C; Jensen T; Juhl CB; Lerche SS; Nørgaard K; Parving HH; Tarnow L; Thorsteinsson B; Pedersen-Bjergaard U
BMC Endocr Disord; 2019 Jul; 19(1):78. PubMed ID: 31337371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
